Clinical Trial: Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or U
Brief Summary: The purpose of this study is to see what amount of radiation is safe to give to rectal or anal cancer patients who are being treated with a procedure called brachytherapy.
Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center
Current Primary Outcome: maximum tolerated dose (MTD) [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome: tumor response [ Time Frame: 3, 6, and 12 months ]
Original Secondary Outcome: tumor response [ Time Frame: 3, 6, and 12 months ]
Information By: Memorial Sloan Kettering Cancer Center
Dates:
Date Received: July 22, 2014
Date Started: July 2014
Date Completion:
Last Updated: January 11, 2017
Last Verified: January 2017